Business
Publication of 2025 Annual Report
Oxford BioDynamics Plc has published its annual report and accounts for the year ended 30 September 2025, making it available on their website and posting hard copies to shareholders. The company, which specializes in precision clinical diagnostics using its EpiSwitch® 3D genomics platform, will hold its Annual General Meeting on 26 January 2026. Disclaimer*
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\n \n \n\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nPublication of 2025 Annual Report\nOxford, UK - 22 December 2025 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that its annual report and accounts for the year ended 30 September 2025 (\"Annual Report\") is available in electronic form on its website at www.oxfordbiodynamics.com/investors/financial-results. Hard copies of the report (incorporating the Notice of Annual General Meeting) will be posted to shareholders today.\nAs stated in the preliminary results announcement on 16 December 2025, the Company's Annual General Meeting will be held at 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK on 26 January 2026 at 11.00 am.\n-Ends-\nFor further details please contact:\n\n\n\n\n Oxford BioDynamics Plc\n\n\nTel: +44 (0)1865 518910\n\n\n\n\nIain Ross Executive Chairman\nPaul Stockdale, CFO\n\n\n\n\n\n\n\nShore Capital - Nominated Adviser and Broker\n\n\nTel: +44 (0)20 7408 4090\n\n\n\n\nStephane Auton / Lucy Bowden\n\n\n\n\n\n\n\nOAK Securities - Joint Broker\n\n\nTel: +44 (0)20 3973 3678\n\n\n\n\nMatthew Clarke / Tim Dainton / Calvin Man\n\n\n\n\n\n\n\nCamarco - Financial PR\n\n\nTel: +44 (0)20 3757 4980\n\n\n\n\nMarc Cohen / Tilly Butcher / Fergus Young\n\n\[email protected]\n\n\n\n\n \n \nNotes to Editors\nAbout Oxford BioDynamics Plc\nOxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.\nCurrently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.\nThe tests are based on OBD's proprietary 3D genomic bioma...